Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 48, Issue 12, 1999, Pages 1589-1595

  Glueck, C J ^a   Wang, Ping ^b   Fontaine, Robert N ^b   Sieve Smith, Luann ^b   Tracy, Trent ^b   Moore, Sarah K ^b  

^a Cholesterol Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SPONTANEOUS ABORTION;

EID: 0032712919     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90250-0     Document Type: Article

References (42)

1. Younis JS, Ohel G, Brenner B, et al: Familial thrombophilia - The scientific rationale for thrombophylaxis in recurrent pregnancy loss? Hum Reprod 12:1389-1390, 1997
2. Brenner B, Blumenfeld Z: Thrombophilia and fetal loss. Blood Rev 11:72-79, 1997
3. Gris JC, Ripart-Neveu S, Maugard C, et al: Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 77:1096-1103, 1997
4. Rai RS, Regan L, Chitolie A, et al: Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 103:842-844, 1996
5. Younis JS: Factor V Leiden - A novel etiology of the long-standing thrombosis theory for recurrent pregnancy loss. Am J Obstet Gynecol 178:1107-1108, 1998
6. Richards EM, Makris M, Preston FE: The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol 98:660-661, 1997
7. Brenner B, Maudel H, Lanir N, et al: Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 97:551-554, 1997
8. Kupfermine MJ, Eldor A, Steinman N, et al: Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 240:9-13, 1999
9. Rand JH, Wu XX, Andree HA, et al: Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 337:154-160, 1997
10. Bick RL, Madden J, Heller KB, et al: Recurrent miscarriage: Causes, evaluation, and treatment. Medscape Womens Health 3:2, 1998 (abstr)
11. Lima F, Khamashta MA, Buchanan NM, et al: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14:131-136, 1996
12. Birdsall MA, Lockwood GM, Ledger WL, et al: Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod 11:1185-1189, 1996
13. Estelles A, Grancha S, Gilabert J, et al: Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol 149:1229-1239, 1996
14. Halligan A, Bonnar J, Sheppard B, et al: Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynaecol 101:488-492, 1994
15. Gris JC, Neveu S, Mares P, et al: Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 122:606-615, 1993
16. Liddell HS, Sowden K, Farquhar CM: Recurrent miscarriage: Screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Ob Gynaecol 37:402-406, 1997
17. Clifford K, Rai R, Watson H, et al: An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases. Hum Reprod 9:1328-1332, 1994
18. Watson H, Kiddy DS, Hamilton-Fairley D, et al: Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 8:829-833, 1993
19. Homburg R, Levy T, Berkovitz D, et al: Gonadotrophin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil Steril 59:527-531, 1993
20. Clifford K, Rai R, Watson H, et al: Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomized controlled trial. BMJ 312:1508-1511, 1996
21. Homborg R, Armar NA, Eshel A, et al: Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 297:1024-1026, 1988
22. Balen AH, Tan SL, MacDougall J, et al: Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 8:959-964, 1993
23. Okon MA, Laird SM, Tuckerman EM, et al: Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 69:682-690, 1998
24. Doldi N, Gessi A, Destafani A, et al: Polycystic ovary syndrome: Anomalies in progesterone production. Hum Reprod 13:290-293, 1998
25. Velazquez EM, Mendoza SG, Hamer T, et al: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654, 1994
26. Velazquez EM, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90:392-395, 1997
27. Velazquez EM, Mendoza SG, Wang P, et al: Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 46:454-457, 1997
28. Glueck CJ, Wang P, Fontaine R, et al: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48:511-519, 1999
29. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 83:3078-3082, 1998
30. Ferriman D, Gallwey JD: Clinical assessment of body hair growth. J Clin Endocrinol Metab 21:1440-1447, 1961
31. Glueck CJ, Bell Howard, Vadlamani L, et al: Heritable thrombophilia and hypofibrinolysis: Possible causes of retinal vein occlusion. Arch Ophthalmol 117:43-49, 1999
32. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
33. Takeuchi T, Nishii O, Okamura T, et al: Free testosterone and abortion in early pregnancy. Int J Gynaecol Obstet 43:151-156, 1993
34. Coetzee EJ, Jackson WP: Metformin in management of pregnant insulin-dependent diabetics. Diabetologia 16:241-245, 1979
35. Coetzee EJ, Jackson WP: The management of non insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1:281-287, 1985-86
36. Glueck CJ, Glueck HI, Welch M, et al: Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost 71:195-198, 1994
37. Glueck CJ, Freiberg R, Tracy T, et al: Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop 334: 43-56, 1997
38. Glueck CJ, Freiberg R, Gruppo R, et al: Thrombophilia and hypofibrinolysis: Reversible pathogenetic etiologies of osteonecrosis in adults and in children (Legg-Perthes disease). AOA International Symposium on Osteonecrosis, in Urbaniak JR, Jones JP Jr (eds): Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL, American Academy of Orthopedic Surgeons, 1997, pp 105-110
39. Glueck CJ, Crawford A, Roy D, et al: Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg Am 78:3-13, 1996
40. Glueck CJ, Brandt G, Gruppo R, et al: Resistance to activated protein C and Legg-Perthes disease. Clin Orthop 338:139-152, 1997
41. Nelson-Piercy C, Letsky EA, de Swiet M: Low-molecular weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176:1062-1068, 1997
42. Gris JC, Neuveu S, Tailland ML, et al: Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost 73:362-367, 1995